Myriad Genetics (MYGN) Short-term Investments (2010 - 2024)

Myriad Genetics (MYGN) has reported Short-term Investments for 15 consecutive years, with $4.9 million the latest figure, recorded in Q2 2024.

• In Q2 2024, Short-term Investments fell 73.94% year-over-year to $4.9 million; the TTM figure through Jun 2024 stood at $4.9 million (down 73.94% YoY), while the FY2023 annual figure was $8.8 million, down 84.83% from the prior year.
• Short-term Investments declined to $4.9 million in Q2 2024 per MYGN's latest filing, from $7.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $103.2 million in Q1 2022 and bottomed at $4.9 million in Q2 2024.
• Historically, Short-term Investments has averaged $46.4 million across 5 years, with a median of $44.0 million in 2020.
• Annual changes were most pronounced in 2022 — Short-term Investments surged 279.41% — and 2023, when it plunged 87.52%.
• Myriad Genetics' Short-term Investments stood at $33.7 million in 2020, then jumped by 141.54% to $81.4 million in 2021, then slipped by 28.75% to $58.0 million in 2022, then slumped by 84.83% to $8.8 million in 2023, then sank by 44.32% to $4.9 million in 2024.
• Business Quant data shows MYGN's Short-term Investments at $4.9 million in Q2 2024, $7.4 million in Q1 2024, and $8.8 million in Q4 2023.